Biomonitoring of Perfluoroalkyl Acids in Human Urine and Estimates of Biological Half-Life
Top Cited Papers
- 27 August 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Environmental Science & Technology
- Vol. 47 (18), 10619-10627
- https://doi.org/10.1021/es401905e
Abstract
Perfluoroalkyl acids (PFAAs) are persistent and bioaccumulative compounds that have been associated with adverse health outcomes. In human blood, PFAAs exist as both linear and branched isomers, yet for most linear homologues, and for all branched isomers, elimination rates are unknown. Paired blood and urine samples (n = 86) were collected from adults in China. They were analyzed by a sensitive isomer-specific method that permitted the detection of many PFAAs in human urine for the first time. For all PFAAs except perfluoroundecanoate (PFUnA), levels in urine correlated positively with levels in blood. Perfluoroalkyl carboxylates (PFCAs) were excreted more efficiently than perfluoroalkane sulfonates (PFSAs) of the same carbon chain-length. In general, shorter PFCAs were excreted more efficiently than longer ones, but for PFSAs, perfluorooctanesulfonate (PFOS, a C8 compound) was excreted more efficiently than perfluorohexanesulfonate (PFHxS, a C6 compound). Among PFOS and perfluorooctanoate (PFOA) isomers, major branched isomers were more efficiently excreted than the corresponding linear isomer. A one-compartment model was used to estimate the biological elimination half-lives of PFAAs. Among all PFAAs, the estimated arithmetic mean elimination half-lives ranged from 0.5 ± 0.1 years (for one branched PFOA isomer, 5m-PFOA) to 90 ± 11 years (for one branched PFOS isomer, 1m-PFOS). Urinary excretion was the major elimination route for short PFCAs (C ≤ 8), but for longer PFCAs, PFOS and PFHxS, other routes of excretion likely contribute to overall elimination. Urinary concentrations are good biomarkers of the internal dose, and this less invasive strategy can therefore be used in future epidemiological and biomonitoring studies. The very long half-lives of long-chain PFCAs, PFHxS, and PFOS isomers in humans stress the importance of global and domestic exposure mitigation strategies.Keywords
This publication has 40 references indexed in Scilit:
- Serum Vaccine Antibody Concentrations in Children Exposed to Perfluorinated CompoundsJAMA, 2012
- Serum Perfluorinated Compound Concentration and Attention Deficit/Hyperactivity Disorder in Children 5–18 Years of AgeEnvironmental Health Perspectives, 2011
- Perfluoroalkyl Chemicals and Chronic Kidney Disease in US AdultsAmerican Journal of Epidemiology, 2011
- Exposure to Polyfluoroalkyl Chemicals and Attention Deficit/Hyperactivity Disorder in U.S. Children 12–15 Years of AgeEnvironmental Health Perspectives, 2010
- The occurrence of perfluorinated alkyl compounds in human milk from different regions of ChinaEnvironment International, 2010
- Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West VirginiaEnvironmental Health Perspectives, 2010
- Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with Uric Acid among Adults with Elevated Community Exposure to PFOAEnvironmental Health Perspectives, 2010
- Perfluorinated Chemicals and Fetal Growth: A Study within the Danish National Birth CohortEnvironmental Health Perspectives, 2007
- Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production WorkersEnvironmental Health Perspectives, 2007
- Perfluorooctanesulfonate and Related Fluorochemicals in Human Blood from Several CountriesEnvironmental Science & Technology, 2004